Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Barbara Acevedo"'
Autor:
Pedram Razavi, Rohan C Parikh, Barbara Acevedo, Abigail Hitchens, Mehnaj Ahmed, Anton Safonov, Emanuela Ferraro, Komal Jhaveri, Michelle Sidel, Stacey Simmons, Mark Robson, Sarat Chandarlapaty, Sanjeev Balu
Publikováno v:
Cancer Research. 82:P1-18
Background: Oncogenic mutations involving PIK3CA gene (PI3Kα) are observed in over 40% of patients with hormone receptor-positive (HR+) advanced breast cancer (ABC). Clinical efficacy of PI3K inhibition was demonstrated in a recent trial, but data o
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::6eb3d9d9d649ab635eb8503581b5c76e
https://doi.org/10.1158/1538-7445.sabcs21-p1-18-18
https://doi.org/10.1158/1538-7445.sabcs21-p1-18-18
Autor:
Anton Safonov, Chai Bandlamudi, Paulino Tallón de Lara, Emanuela Ferraro, Fatemeh Derakhshan, Marie Will, Mark Donoghue, Pier Selenica, Joshua Drago, Ezra Rosen, Carlos dos Anjos, Elaine Walsh, Elizabeth A Comen, Mehnaj Ahmed, Barbara Acevedo, Ahmet Zehir, Michael F Berger, David Solit, Larry Norton, Ronglai Shen, Zsofia Stadler, Simon Powell, Jorge S Reis-Filho, Sarat Chandarlapaty, Mark Robson, Pedram Razavi
Publikováno v:
Cancer Research. 82:GS4-08
Background: Germline genetic alterations are established mediators of breast carcinogenesis, often giving rise to specific forms of genomic instability. BRCA1/2 pathogenic variants (PVs) are emblematic of this phenomenon through their induction of ho
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::64c3625e8f520fdb49b11a84013dc863
https://doi.org/10.1158/1538-7445.sabcs21-gs4-08
https://doi.org/10.1158/1538-7445.sabcs21-gs4-08
Autor:
Emanuela Ferraro, Anton Safonov, Yuan Chen, Charlie White, Antonio Marra, Mehnaj Ahmed, Barbara Acevedo, Chau T Dang, Shanu Modi, David B. Solit, Larry Norton, Mark E. Robson, Jorge Reis-Filho, Sarat Chandarlapaty, Pedram Razavi
Publikováno v:
Cancer Research. 83:P4-02
Background: HER2 positive (HER2+) breast cancers harboring downstream MAPK or PI3K pathway alterations manifest persistent downstream signaling on anti-HER2 inhibitors with metastatic patients having worse outcomes on first line trastuzumab and pertu
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::91b2364e9bc265a59372bc51a2566835
https://doi.org/10.1158/1538-7445.sabcs22-p4-02-01
https://doi.org/10.1158/1538-7445.sabcs22-p4-02-01
Autor:
Jane Park, Srinivasaraghavan Kannan, Eneda Toska, Maurizio Scaltriti, Charles L. Sawyers, Emiliano Cocco, Ralf Jauch, Wouter R. Karthaus, Dara S. Ross, Daisylyn Senna Tan, Yanyan Cai, Fan Wu, Erik Ladewig, Mirna Sallaku, Matthew Witkin, José Baselga, Jesper L.V. Maag, Jorge S. Reis-Filho, Sik Y. Ho, Chandra S. Verma, Srushti Kittane, Barbara Acevedo, Amaia Arruabarrena-Aristorena, Lorenzo Ferrando, Richard Koche, Pier Selenica, Pedram Razavi
Publikováno v:
Cancer Cell
Mutations in the pioneer transcription factor FOXA1 are a hallmark of estrogen receptor-positive (ER(+)) breast cancers. Examining FOXA1 in ~5,000 breast cancer patients identifies several hotspot mutations in the Wing2 region and a breast cancer-spe
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a301bfbe753d5649c1f16465194a84e2
https://doi.org/10.1016/j.ccell.2020.08.003
https://doi.org/10.1016/j.ccell.2020.08.003